. "Appendix E: Prospects for Immunizing Against Cytomegalovirus." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States
Patients with Malignancies (Leukemias)
Category C
# of cases=1,036
100% of cases typically receive 18 additional days ICU at $600/day
= $
11,189,000
100% of cases typically receive additional diagnostic testing and treatment procedures at rate equivalent to daily inclusive hospital rate 18 days at $600/day
= $
11,189,000
TOTAL COST
= $
22,378,000
TOTAL COST FOR CMV
= $
1,000,544,000
Cost of Vaccine Preventable Illness
Glycoprotein Vaccine for Normal Children
100% of congenital and perinatal infection
= $
435,608,000
100% of mononucleosis and other febrile illnesses
= $
54,261,000
100% of post-transfusion disease in people over 1 year, but 0% in infants under 1 year (25,713 in Category C only)
= $
334,269,000
TOTAL COST
= $
824,138,000
Live Attenuated Vaccine for High-Risk individuals
50% of all disease burden in IC patients (transplant recipients, patients with malignancies)
= $
29,826,000
TOTAL COST
= $
29,826,000
Live Attenuated Vaccine for Nonpregnant Adolescent Females
90% of congenital and perinatal infection
= $
392,047,000
TOTAL COST
= $
392,047,000
References
Adler, S.P., T.Chandrika, L.Lawrence, and J.Baggett. 1983. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr. Infect. Dis. 2(2):114–118.
Albrecht, T., and F.Rapp. 1973. Malignant transformation of hamster embryo fibroblasts following exposure to ultraviolet-irradiated human cytomegalovirus. Virology 55:53–61.
Alford, C. 1983. Personal communication. University of Alabama, Birmingham.
